Emerging and Existing Treatment Regimens for Transplant-Ineligible DLBCL

Season 2, Episode 5,  Jun 30, 12:00 PM

In this episode, CancerNetwork spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL).

Salles discussed some of the available treatment options including tafasitamab, CAR T-cell therapies, selinexor, and antibody drug conjugates (ADCs). He also looked ahead at some of the upcoming research on the horizon, including the B-MIND trial investigating tafasitamab or rituximab plus bendamustine.